– USA, NY – Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced the appointment of Dr. Paul Grint (MD) as Chairman of the Board of Directors.
“We are delighted to welcome Paul to our Board of Directors. He is a biotechnology industry veteran who brings three decades of clinical leadership experience that will prove invaluable to the company as we continue to grow and advance our pipeline,” said Co-Founder and CEO, Dr. Rob Coleman. Paul brings extensive expertise in research and development, operations, fundraising, and corporate governance along with years of Board experience with both public and private companies. He will be a great asset to Codagenix as we look to achieve key upcoming milestones, such as completion of our Phase 3 clinical trial of CoviLiv.”
About Dr. Paul Grint
Dr. Grint has over 30 years of industry experience and was recently CEO of Ampliphi Biosciences. Before Ampliphi, Dr. Grint served as CEO and CMO of Regulus Therapeutics. Previous leadership positions include President of Cerexa, SVP of Early Development and Internal Medicine at Forest Research Institute and CMO and Head of Development at Kalypsys. He currently serves on the Boards of Directors of Cardea Bio, Synedgen, Inhibikase Therapeutics, and Persephone Biosciences. He is also an Entrepreneur in Residence, at the Office of Innovation and Commercialization, at the University of California, San Diego.
“I am honored to join Codagenix at such a pivotal time, as the organization leverages its impressive synthetic biology-based platform to pioneer a new era of live-attenuated vaccines and immuno-oncology therapies,” said Dr. Grint. “I look forward to partnering with this talented Board and management team to take on the biggest threats in infectious disease and cancer.”
Dr. Grint earned his Bachelor of Science in Infection and Immunity from St. Mary’s Hospital Medical School, London, and his Bachelor of Medicine, and Bachelor of Surgery from the University of London, St. Bartholomew’s Hospital Medical College, London.
About Codagenix, Inc.
Codagenix is a clinical-stage biotechnology company leading a new era of live vaccines and viral therapeutics. The company’s breakthrough platform combines live-attenuated virus design with cutting-edge codon deoptimization for powerful synthetic biology-based solutions to take on our most significant threats in infectious disease, cancer, and animal health. Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University; is supported by Adjuvant Capital, TopSpin Partners, and Euclidean Capital; and has ongoing research and license programs with various federal agencies.
For more information: https://codagenix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
